Form 4: Beyond Air Director Exercises and Reprices Stock Options

A Beyond Air director, Erick Lucera, exercised and repriced multiple stock options on November 22, 2024, following a board-approved repricing.

Summary

• Erick Lucera, a director at Beyond Air, Inc., engaged in multiple stock option transactions on November 22, 2024.
• These transactions involved the exercise of existing stock options and the repricing of other options.
• The board of directors approved a repricing of stock options, setting the new exercise price at $0.54 per share, which was the closing price of the company's common stock on that date.
• A total of 285,000 stock options were repriced to $0.54 per share.
• The original exercise prices of the repriced options ranged from $1.53 to $6.87 per share.
• The repriced options were originally granted under the company's 2013 Equity Incentive Plan.

Sentiment

Score: 5

Explanation: The document is neutral, detailing a routine stock option repricing. While it could be seen as a negative signal, it is a common practice and does not indicate a major positive or negative shift.

Positives

• The repricing of stock options at the closing price of $0.54 per share may incentivize the director to align with shareholder interests.
• The repricing may help retain key personnel by making their options more valuable.

Negatives

• The repricing of stock options could be seen as a negative signal, potentially indicating that the original option prices were not achievable.
• The reduction in exercise price could dilute the value of existing shares.

Risks

• The repricing of options could lead to concerns about potential dilution of existing shareholders' equity.
• The repricing could be perceived negatively by investors if it is seen as a lack of confidence in the company's future stock price performance.

Industry Context

Stock option repricing is a common practice, particularly in situations where a company's stock price has declined, to maintain the incentive value of options for employees and directors.

Comparison to Industry Standards

• Stock option repricing is a common practice in the biotech industry, especially for companies with volatile stock prices.
• Many companies use equity incentive plans to attract and retain key personnel, and repricing is a tool to ensure these incentives remain effective.
• The specific terms of the repricing, such as the new exercise price and vesting schedule, are generally aligned with industry standards and the company's compensation policies.

Stakeholder Impact

• Shareholders may experience a slight dilution of their equity due to the repricing of stock options.
• Employees and directors holding stock options may benefit from the reduced exercise price.

Key Dates

Keywords

stock options, option repricing, insider trading, Erick Lucera, Beyond Air, equity incentive plan, director, SEC Form 4